This database contains 114 studies, archived under the term: "baseline"
Click here to filter this large number of results.
Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for […]
No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer’s disease
Objective: Work in experimental animals suggests that an interaction with dopaminergic networks might explain some of the therapeutic effects of the cholinesterase inhibitor class of drugs. This study aimed to test whether acute (single 5 mg) or 4–8 weeks (5–10 mg) of treatment with oral donepezil would elicit measurable striatal dopamine (DA) release in patients […]
Vitamins B₁₂, B₆, and folic acid for cognition in older men
[Correction Notice: An erratum for this article was reported in Vol 77(8) of Neurology (see record [rid]2011-21984-022[/rid]). In the original article, the daily dose of vitamin B12 used in the trial was reported as 400 μg, but it should have been 500 μg.] Objective: To investigate whether supplementing older men with vitamins B12, B6, and […]